---
document_datetime: 2025-10-02 11:41:08
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/oxlumo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: oxlumo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6328403
conversion_datetime: 2025-12-28 09:58:11.297634
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Oxlumo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 24/07/2025                          | 04/08/2025                                  | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000263375                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.8, and 5.1 of the SmPC in order update the description of clinical efficacy and safety data based on final results from the Extension Period of study ALN-GO1-004 (ILLUMINATE-B) listed as a category 3 study in the RMP; this is a Phase 3 multicentre, multinational, single-arm, open- label study with an extended dosing period designed to demonstrate the efficacy and safety of lumasiran in reducing urinary and plasma oxalate in PH1 patients <6 years of age and with relatively preserved renal function; In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000278833 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Change in the testing frequency of specification parameter, from routine testing to skip or periodic testing - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Renewal - 5 year / EMA/R/0000245133   | - Renewal - Accepted   | 18/06/2025   | 04/08/2025   | SmPC, Annex II, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Oxlumo in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------------------------|------------------------|--------------|--------------|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248463            | - -                    |              |              |                                    | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing lumasiran (Oxlumo) remains unchanged and therefore recommends the maintenance of the marketing authorisation(s).            |